Latest News about AZN
Recent news which mentions AZN
   Europe Approves AstraZeneca's Two Combo Therapies For Prostate, Bile Duct Cancer Settings
   
  
  
  December 21, 2022
  From Benzinga
 
   Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
   
  
  
  December 20, 2022
  From Benzinga
 
   Could AstraZeneca's Asthma Drug Candidate Generate Billions?
   
  
  
  December 20, 2022
  From Motley Fool
 
   AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
   
  
  
  December 19, 2022
  From Benzinga
 From Benzinga
 
   AstraZeneca’s Forxiga gets EU approval recommendation for symptomatic chronic heart failure
   
  December 19, 2022
  Tickers 
   AZN
  
  
  From MarketWatch
 
   AstraZeneca’s Imfinzi plus Imjudo recommended for approval in the EU
   
  December 19, 2022
  Tickers 
   AZN
  
  
  From MarketWatch
 
   Guardant Health (GH) Stock Sinks on Disappointing Blood Test Results
   
  
  
  December 16, 2022
  From InvestorPlace
 
   2 Best Biotech Stocks to Buy Right Now
   
  
  
  December 16, 2022
  From Motley Fool
 From Benzinga
 
   Netflix, Workday, Costco, Caterpillar and more: These stocks are Cowen’s favorites for 2023
   
  
  
  December 10, 2022
  From MarketWatch
 
   2 Top Healthcare Stocks to Buy for the Long Haul
   
  
  
  December 09, 2022
  From Motley Fool
 
   AstraZeneca Highlights First Results From Datopotamab Study In Pretreated Breast Cancer Patients
   
  
  
  December 09, 2022
  From Benzinga
 
   AstraZeneca Highlights Detailed Data From Two Breast Cancer Trials
   
  
  
  December 08, 2022
  From Benzinga
 
   AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
   
  
  
  December 07, 2022
  From Benzinga
 
   US Supports Delay On COVID Patent Waiver Extension Decision
   
  
  
  December 06, 2022
  From Benzinga
 
   Is Amgen Stock a Buy for Income Investors?
   
  
  
  December 02, 2022
  From Motley Fool
 
   2 Stocks That Could Surprise Investors in 2023
   
  
  
  December 01, 2022
  From Motley Fool
 
   Why Shares of Compugen Rose 16.5% on Wednesday
   
  
  
  November 30, 2022
  From Motley Fool
 
   Analyst Says Coinbase 'A Waste Of Time', Taylor Swift's Concert Fiasco Under DOJ Probe, Shopify Clocks Record Black Friday Sales: Top Stories Monday, Nov. 28
   
  
  
  November 28, 2022
  From Benzinga
 
   AstraZeneca Bets On UK Listed Firm For Lung Diseases
   
  
  
  November 28, 2022
  From Benzinga
 From Benzinga
 
   2 Breakout Growth Stocks to Buy for the Long Haul
   
  
  
  November 19, 2022
  From Motley Fool
 
   2 Stocks to Buy Whether or Not a Recession Is Coming
   
  
  
  November 18, 2022
  From Motley Fool
 
   Why Shares of Compugen Jumped 17.86% on Thursday
   
  
  
  November 17, 2022
  From Motley Fool
 
   How Long Can This Top Stock Continue Defying the Bear Market?
   
  
  
  November 17, 2022
  From Motley Fool
 
   Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
   
  
  
  November 16, 2022
  From Benzinga
 
   Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
   
  
  
  November 15, 2022
  From Benzinga
 
   Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
   
  
  
  November 14, 2022
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.